

Capsaicin Cream is Back

Available at all mainline and shortline wholesalers from January 2026



Available at all Mainline and Shortline Wholesalers

PIP Code: 250-2375

EAN Code: 5017007607403

The product has undergone a change of ownership from Teva to Ennogen

Zacin®
0.025% w/w Cream
Capsaicin

For the symptomatic relief of pain associated with osteoarthritis.

INTENDED FOR UK HEALTHCARE PROFESSIONALS ONLY

Prescribing Information

Zacin 0.025% w/w Cream
Capsaicin 0.025% w/w Cream

Name(s) and active ingredient: Zacin 0.025% w/w Cream Capsaicin 0.025% w/w Cream, capsaicin **Indications:** For the symptomatic relief of pain associated with osteoarthritis. **Posology and method of administration:** Adults and the elderly: For topical administration to unbroken skin. Apply only a small amount of cream (pea size) to affected area 4 times daily. These applications should be evenly spaced throughout the waking hours and not more often than every 4 hours. The cream should be gently rubbed in, there should be no residue left on the surface. Zacin may cause transient burning on application. The burning is observed more frequently when application schedules of more than 4 times daily are used. Hands should be washed immediately after application of Zacin unless hands and fingers are being treated. Zacin should not be applied near the eyes. Pain relief usually begins within the first week of treatment and increases with continuing regular application for the next two to eight weeks. **Not suitable for use in children.** **Method of administration:** For topical administration. **Contraindications:** Zacin cream is contra-indicated for use on broken or irritated skin. Zacin Cream is contra-indicated in patients with hypersensitivity to the active substance or to any of the excipients listed in section 6.1 of SmPC. **Special warnings and precautions for use:** Skin irritation has been reported following application of Zacin. The hands should be washed immediately after application of the cream, unless the hands are the treated areas, in which case, they should be washed 30 minutes after application. Contact with eyes and mucous membranes should be avoided. Patients should avoid taking a hot bath or shower just before or after applying Zacin, as it can enhance the burning sensation. Patients and carers should avoid inhalation of vapours from the cream, as transient irritation of the mucous membranes of the eyes and respiratory tract (including exacerbation of asthma) has been reported. Keep Zacin away from the eyes. Medical advice should be sought if the condition worsens, or clears up then recurs. Tight bandages should not be applied on top of Zacin cream.

Excipients: Benzyl alcohol may cause mild local irritation. Cetyl alcohol may cause local skin reactions (e.g. contact dermatitis). **Interactions:** No interaction studies have been performed. **Fertility, pregnancy and lactation:** The safety of Zacin during pregnancy and lactation has not been established, in either humans or animals. However, in the small amounts absorbed transdermally from Zacin Cream, it is considered unlikely that capsaicin will cause any adverse effects in humans. **Effects on ability to drive and use machines:** Not applicable **Adverse reactions:** See SmPC section 4.8 for full details. Zacin may cause skin irritation or transient burning on application. Irritation of the mucous membranes of the eyes and respiratory tract (such as nasal and throat irritation) on application of Zacin cream has been reported rarely, resulting in symptoms such as coughing, sneezing and runny eyes. These events are usually mild and self-limiting. There have been a few reports of dyspnoea, wheezing and exacerbation of asthma. **Presentations & Price:** Aluminium tubes with epoxyphenolic lining and polypropylene spiked cap containing 45 g of Zacin Cream 0.025% - £ 17.71. **Legal Classification:** Prescription Only Medicine (POM). **Date of last revision of SmPC:** 05/12/2025. **Marketing Authorisation Holder:** Ennogen IP Ltd, Unit G4, Riverside Industrial Estate, Riverside Way, Dartford, DA1 5BS. **Marketing Authorisation Number:** PL 55612/0089. **Job code:** GEN-GB-01857. **Date of flyer preparation:** January 2026. Please refer to the Summary of Product Characteristics (SmPC) for full details of Prescribing Information. **Prescribing Information can be found here:** www.medicines.org.uk/emc/product/101757/smpc

Adverse events should be reported.

Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Ennogen IP Ltd on Tel: 01322 629 220 or medicalinformation@ennogen.com. For a copy of the SmPC or further medical information, please contact: medicalinformation@ennogen.com

Contact details: Ennogen IP Ltd, Unit G4, Riverside Industrial Estate, Riverside Way, Dartford, DA1 5BS.
Email: info@ennogen.com | **Telephone:** +44 (0) 1322 629 220 | **Fax:** +44 (0) 1322 311 897

Ennogen